0001415889-24-015370.txt : 20240604
0001415889-24-015370.hdr.sgml : 20240604
20240604163024
ACCESSION NUMBER: 0001415889-24-015370
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240531
FILED AS OF DATE: 20240604
DATE AS OF CHANGE: 20240604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Domzalski David
CENTRAL INDEX KEY: 0001727794
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 241018607
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VYNE Therapeutics Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 685 ROUTE 202/206 N., SUITE 301
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 800-775-7936
MAIL ADDRESS:
STREET 1: 685 ROUTE 202/206 N., SUITE 301
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics Inc.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics, Inc.
DATE OF NAME CHANGE: 20170728
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
form4-06042024_040620.xml
X0508
4
2024-05-31
0001566044
VYNE Therapeutics Inc.
VYNE
0001727794
Domzalski David
C/O VYNE THERAPEUTICS INC.
685 ROUTE 202/206 N, SUITE 301
BRIDGEWATER
NJ
08807
true
true
false
false
PRESIDENT AND CEO
0
Common Stock
2024-05-31
5
A
0
4429
2.159
A
498589
D
These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2023 and ending on May 31, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2024.
/s/ Mutya Harsch, attorney-in-fact for David Domzalski
2024-06-04